The new policy, revealed by the Department of Health and Human Services on Wednesday, would make vaccines “less available and ...

Announcing first-quarter results, Biogen CEO Chris Viehbacher admitted that tariffs are “a new topic for us,” but said he ...

Jefferies analysts said Moderna’s first quarter was “in line,” with a miss on revenue offset by a beat on earnings per share.

According to CEO Daniel Vitt, clinical and disability-related outcomes are more relevant than brain volume change for drug ...

Global employee engagement fell two percentage points in 2024, according to Gallup, while BioSpace found that workforce ...

To say, as CEO David Ricks did, that this was a good quarter, is an understatement. Mounjaro in diabetes brought in $3.84 ...

The FDA has lost several senior employees in recent weeks, including some who have been at the agency for more than two ...

When it comes to vaccination, the COVID-19 pandemic divided American society. President Donald Trump and his new Health and ...

Eli Lilly CEO David Ricks is confident that weight loss med Zepbound is gaining market share at the expense of Wegovy, even as its rival strikes deals with CVS and Hims & Hers pharmacies.

Johnson & Johnson ’s anti-FcRn antibody nipocalimab has been approved by the FDA to treat generalized myasthenia gravis. The drug will be marketed under the brand name Imaavy.

Policy uncertainties are impacting biopharma dealmaking from continent to continent, with companies being asked to walk a ...

Entrada is paring back its research staff even as it gears up to hire employees to support a planned clinical trial for a ...